232 related articles for article (PubMed ID: 34033207)
1. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.
Kridin K; Schonmann Y; Damiani G; Peretz A; Onn E; Bitan DT; Cohen AD
Dermatol Ther; 2021 Jul; 34(4):e15003. PubMed ID: 34033207
[TBL] [Abstract][Full Text] [Related]
2. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
3. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in the Patterns of Systemic Agent use Among Patients With Psoriasis: A Retrospective Cohort Study in Quebec, Canada.
Milan R; LeLorier J; Brouillette MJ; Holbrook A; Litvinov IV; Rahme E
Front Pharmacol; 2022; 13():810309. PubMed ID: 35242034
[No Abstract] [Full Text] [Related]
5. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
Thein D; Egeberg A; Skov L; Loft N
JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
[TBL] [Abstract][Full Text] [Related]
6. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
Kridin K; Schonmann Y; Solomon A; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
J Dermatolog Treat; 2022 Jun; 33(4):2014-2020. PubMed ID: 33759683
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study.
Yousaf A; Gayam S; Feldman S; Zinn Z; Kolodney M
J Am Acad Dermatol; 2021 Jan; 84(1):70-75. PubMed ID: 32926977
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.
Wu JJ; Guérin A; Sundaram M; Dea K; Cloutier M; Mulani P
J Am Acad Dermatol; 2017 Jan; 76(1):81-90. PubMed ID: 27894789
[TBL] [Abstract][Full Text] [Related]
9. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
[TBL] [Abstract][Full Text] [Related]
11. Nineteen months into the pandemic, what have we learned about COVID-19-related outcomes in patients with psoriasis?
Kridin K; Schonmann Y; Onn E; Bitan DT; Weinstein O; Shavit E; Cohen AD
J Cosmet Dermatol; 2022 Dec; 21(12):6549-6553. PubMed ID: 36056782
[TBL] [Abstract][Full Text] [Related]
12. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
Buckley LH; Xiao R; Perman MJ; Grossman AB; Weiss PF
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):215-220. PubMed ID: 31646743
[TBL] [Abstract][Full Text] [Related]
14. Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study.
Curtis JR; Zhou X; Rubin DT; Reinisch W; Yazdany J; Robinson PC; Chen Y; Benda B; Madsen A; Geier J
J Rheumatol; 2022 Mar; 49(3):320-329. PubMed ID: 34782447
[TBL] [Abstract][Full Text] [Related]
15. TNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic.
Mazloom SE; Yan D; Hu JZ; Ya J; Husni ME; Warren CB; Fernandez AP
J Am Acad Dermatol; 2020 Dec; 83(6):1590-1598. PubMed ID: 30576759
[TBL] [Abstract][Full Text] [Related]
16. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
[TBL] [Abstract][Full Text] [Related]
17. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
Kridin K; Zirpel H; Mruwat N; Ludwig RJ; Thaci D
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2319-2326. PubMed ID: 37466275
[TBL] [Abstract][Full Text] [Related]
19. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study.
Kridin K; Schonmann Y; Tzur Bitan D; Damiani G; Peretz A; Weinstein O; Cohen AD
Am J Clin Dermatol; 2021 Sep; 22(5):709-718. PubMed ID: 34060006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
